Kezar Life Sciences, Inc. (KZR) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

In the chart below, we highlight the unlikely scenarios needed to ... Lilly have set the bar for efficacy and side effect ...

Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity ...

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Last month, Eli Lilly announced it would reduce the cost of the lowest dose of its drug Zepbound to around $400 a month. It also launched its own telehealth company, LillyDirect. Readdy ...

Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

If anything, the four-week supply of the 2.5 mg Zepbound single-dose vial at $399 (self-pay) is not too far from HIMS' compounded GLP-1 injectables from $199 monthly (based on a 12-month plan).

Compounding pharmacies have used a legal provision that allows them to make knockoff versions of Lilly’s Zepbound and Mounjaro while they are in a shortage. While Lilly has raised questions ...